1. Home
  2. SLVM vs NVAX Comparison

SLVM vs NVAX Comparison

Compare SLVM & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$38.90

Market Cap

1.9B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.54

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
NVAX
Founded
1898
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
SLVM
NVAX
Price
$38.90
$9.54
Analyst Decision
Buy
Hold
Analyst Count
2
9
Target Price
$54.00
$11.33
AVG Volume (30 Days)
279.3K
4.3M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
4.54%
N/A
EPS Growth
N/A
309.76
EPS
3.24
2.58
Revenue
$3,351,000,000.00
$1,123,479,000.00
Revenue This Year
$0.98
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
$12.27
$3.89
Revenue Growth
N/A
64.69
52 Week Low
$37.52
$5.01
52 Week High
$68.76
$11.85

Technical Indicators

Market Signals
Indicator
SLVM
NVAX
Relative Strength Index (RSI) 24.93 47.45
Support Level $38.06 $9.14
Resistance Level $46.59 $10.42
Average True Range (ATR) 1.58 0.60
MACD -0.48 -0.10
Stochastic Oscillator 1.62 19.40

Price Performance

Historical Comparison
SLVM
NVAX

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: